Leqvio plus individually optimized lipid-lowering therapy (LLT) achieved LDL-C targets within 90 days vs. 31% of patients on placebo plus LLT 1 Patients on Leqvio plus LLT were 43% less likely to ...

Monthly olezarsen reduced triglyceride levels by up to 60% at 6 months among patients with moderate hypertriglyceridemia and elevated cardiovascular risk.Treatment with olezarsen (Tryngolza, Ionis ...

Study results show mortality benefit from low-dose digitoxin for heart failure in symptomatic patients with reduced ejection fraction.

About four in 10 patients taking the drug reached a healthy blood pressure level – which is typically considered under 130mmHg – compared with fewer than two in 10 taking a placebo, having previously ...

Adding baxdrostat to background antihypertensive therapy led to substantial reductions in seated systolic blood pressure after 12 weeks of treatment among patients with uncontrolled or resistant ...

This decision was informed by the comprehensive KARDIA Phase II programme, including KARDIA 1, KARDIA 2 and the most recent KARDIA-3 study evaluating the efficacy and safety of zilebesiran in patients ...

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite ...

MADRID -- For uncontrolled or treatment-resistant hypertension, adding the novel aldosterone synthase inhibitor baxdrostat improved blood pressure in the randomized BaxHTN trial.

Doctors may soon have a new way to treat high blood pressure, even among people for whom medicines haven’t worked well in the ...

The Mirror travelled to the world’s biggest heart conference to see unveiling of new class of drug called baxdrostat - hailed as 'a triumph of scientific discovery’ ...

AstraZeneca plans to file for regulatory approval of its experimental blood pressure treatment before the end of the year, a ...